MetaVia Inc. Sponsors MASH-TAG 2026 Conference, Focusing on Cardiometabolic Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Conference Participation: MetaVia will participate and sponsor the 10th Annual MASH-TAG 2026 Conference from January 8-10 at Chateaux Deer Valley in Park City, Utah, aiming to enhance its influence in the cardiometabolic disease sector.
- Product Development: The company is developing DA-1726 as an innovative treatment for obesity, which demonstrated best-in-class weight loss potential in a Phase 1 multiple ascending dose trial, positioning it for market leadership.
- New Drug Research: Vanoglipel (DA-1241), a novel GPR119 agonist, has shown positive effects on liver inflammation and lipid metabolism in preclinical studies, potentially offering new solutions for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Clinical Trial Progress: In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action alongside glucose-lowering effects, further solidifying MetaVia's R&D capabilities in the treatment of cardiometabolic diseases.
MTVA
$9.19+Infinity%1D
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 9.67 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.190
Low
5.00
Averages
9.67
High
12.00
Current: 9.190
Low
5.00
Averages
9.67
High
12.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
